Kelli Williams
Pediatric Allergy/Immunology · Charleston, SCNPI 1902030042
Payments from drug & device makers
Across 233 payments — averaging $2768.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$254K
- GSK$146K
- Astrazeneca UK Limited$84K
- Amgen$77K
- Pharming Healthcare, Inc.$43K
- Novartis$15K
- plus $26K from 15 others
Across 23 payments — averaging $5155.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ADMA Biomanufacturing LLC$117K
- GSK$1K
- Pharming Healthcare, Inc.$500
What the payments were for
- Consulting fees$81,00254%
- Speaking & faculty fees$55,12337%
- Travel & lodging$8,7856%
- Food & beverage$4,8893%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 28 | $253,885 |
| GSK | 27 | $146,369 |
| Astrazeneca UK Limited | 6 | $83,773 |
| Amgen(2 entities) | 54 | $77,095 |
| Pharming Healthcare, Inc. | 59 | $42,971 |
| Novartis | 2 | $15,461 |
| Sumitomo Pharma America, Inc. | 11 | $7,110 |
| ADMA Biomanufacturing LLC | 5 | $6,281 |
| Blueprint Medicines Corporation | 6 | $5,408 |
| Grifols USA, LLC | 4 | $2,365 |
| Pfizer | 10 | $1,890 |
| Genentech USA, Inc. | 3 | $1,537 |
| CSL Behring | 5 | $363 |
| Sobi, Inc | 3 | $259 |
| X4 Pharmaceuticals, Inc. | 1 | $135 |
| Sanofi | 3 | $131 |
| Biocryst US Sales Co., LLC | 2 | $31 |
| Phadia US Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Bio Products Laboratory USA, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric allergy/immunology providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $131,830 |
| Dupixent SyringeDupilumab | 25 | $94,411 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $94,053 |
| Epinephrine | 13 | $2,324 |
| Ipratropium Bromide | 15 | $626 |
| Doxepin Hcl | 14 | $278 |
| Azelastine Hcl | 12 | $224 |
| Sodium Chloride0.9 % Sodium Chloride | 13 | $181 |
| Fluticasone Propionate | 17 | $171 |
| Azithromycin | 16 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $363 | $131,83026 claims |
| PfizerOctagam | $1,890 | $94,05312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric allergy/immunology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.